PMID- 28816796
OWN - NLM
STAT- MEDLINE
DCOM- 20190321
LR  - 20190321
IS  - 1536-3678 (Electronic)
IS  - 1077-4114 (Linking)
VI  - 40
IP  - 2
DP  - 2018 Mar
TI  - Intrathecal Infusion of Haploidentical Nondonor Lymphocytes for Central Nervous 
      System Leukemic Relapse After Haploidentical Hematopoietic Stem Cell 
      Transplantation.
PG  - e129-e132
LID - 10.1097/MPH.0000000000000937 [doi]
AB  - Leukemic relapse in the central nervous system (CNS) after conventional treatment 
      is associated with a poor prognosis. The effectiveness and safety of IV infusion 
      of human leukocyte antigen (HLA)-mismatched lymphocytes for leukemia, and 
      intrathecal (IT) infusion of HLA-mismatched lymphocytes for cerebrospinal fluid 
      (CSF) dissemination of medulloblastoma have been reported. A 13-year-old girl 
      (HLA-A31) was diagnosed as relapsing from Philadelphia chromosome-positive acute 
      leukemia in the CNS after receiving chemotherapy, tyrosine kinase inhibitors, 
      haploidentical hematopoietic stem cell transplantation (HSCT) from her father 
      (HLA-A31), and craniospinal irradiation. We performed an IT infusion of 
      haploidentical lymphocytes from her mother. Peripheral blood mononuclear cells 
      obtained from her mother (HLA-A31) were administered by IT infusion weekly. 
      Examination of CSF 1 week after first IT showed that lymphocyte counts had 
      increased markedly and the breakpoint cluster region/abelson-bearing cells had 
      disappeared. Furthermore, CD3 T cells in the CSF were negative for HLA-A31, and 
      expressed high HLA-DR. These results indicate the infused non-HSCT-donor 
      lymphocytes did not survive, and that the HSCT donor(father)-derived lymphocytes 
      migrated to the CSF and were activated. The patient showed partial remission for 
      2 months following this therapy. Serious adverse reactions and graft versus host 
      disease were not observed. To control leukemic CNS dissemination, haploidentical 
      nondonor lymphocytes might contribute to a graft versus leukemia effect.
FAU - Mayumi, Azusa
AU  - Mayumi A
AD  - Department of Hematology/Oncology, Osaka Medical Center and Research Institute 
      for Maternal and Child Health, Osaka, Japan.
FAU - Sawada, Akihisa
AU  - Sawada A
FAU - Ioi, Aya
AU  - Ioi A
FAU - Higuchi, Kohei
AU  - Higuchi K
FAU - Shimizu, Mariko
AU  - Shimizu M
FAU - Sato, Maho
AU  - Sato M
FAU - Yasui, Masahiro
AU  - Yasui M
FAU - Inoue, Masami
AU  - Inoue M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pediatr Hematol Oncol
JT  - Journal of pediatric hematology/oncology
JID - 9505928
SB  - IM
MH  - Adolescent
MH  - Central Nervous System Neoplasms/*therapy
MH  - Female
MH  - Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Immunotherapy, Adoptive/*methods
MH  - Injections, Spinal
MH  - Leukemia, Myeloid, Acute/*therapy
MH  - Leukocytes, Mononuclear/*transplantation
MH  - Neoplasm Recurrence, Local/*therapy
EDAT- 2017/08/18 06:00
MHDA- 2019/03/22 06:00
CRDT- 2017/08/18 06:00
PHST- 2017/08/18 06:00 [pubmed]
PHST- 2019/03/22 06:00 [medline]
PHST- 2017/08/18 06:00 [entrez]
AID - 10.1097/MPH.0000000000000937 [doi]
PST - ppublish
SO  - J Pediatr Hematol Oncol. 2018 Mar;40(2):e129-e132. doi: 
      10.1097/MPH.0000000000000937.